Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GlobalData Plc
  6. News
  7. Summary
    DATA   GB00B87ZTG26


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

GlobalData : CARsgen's novel pipeline therapy could be beneficial to underserved patients in late-stage advanced HCC, says GlobalData

06/18/2021 | 01:31pm EDT
18 Jun 2021
CARsgen's novel pipeline therapy could be beneficial to underserved patients in late-stage advanced HCC, says GlobalData
Posted in Pharma

CARsgen Therapeutics' novel pipeline therapy for advanced hepatocellular carcinoma (HCC) stands out in the American Society of Clinical Oncology (ASCO) virtual annual meeting for being the first-in-class approach with a unique mechanism of action that targets heavily pretreated advanced HCC patients, says GlobalData, a leading data and analytics company.

Results for multiple HCC clinical trials were presented at the 2021 ASCO virtual annual meeting. CARsgen presented data from a Phase I trial (NCT03980288) of its fourth-generation chimeric antigen receptor T (CAR-T) cells targeting glypican-3 (GPC3). Fourth-generation CAR-T cells are additionally engineered to secrete a transgenic cytokine upon CAR signaling in the targeted tumor tissue. As a result, in addition to the direct antitumor attack, they can trigger T cells to eliminate antigen-negative cancer cells at the target site. GPC3 is a cell-surface glycoprotein that is highly expressed in HCC and is thus being evaluated as a target for HCC immunotherapy.

In this study, CARSgen's fourth-generation CAR-GPC3 T cells in combination with the tyrosine kinase inhibitors (TKIs) Nexavar (sorafenib) or Stivarga (regorafenib) demonstrated manageable safety and potential antitumor activity for hepatitis B virus (HBV)-related metastatic HCC patients who have been previously treated with systemic therapy.

Key opinion leaders (KOLs) interviewed by GlobalData noted that CAR-T cells or adoptive cellular therapy is an emerging area that may change HCC treatment practice in the future.

Mandana Emamzadeh, PhD, Pharma Analyst at GlobalData, comments: 'The majority of late-stage pipeline drugs for advanced HCC are for use in the first-line setting, which has the highest number of treated cases. Therefore, subsequent lines of therapy are being overlooked by drug developers, despite high unmet need. However, CARsgen Therapeutics conducted the study of its CAR-T cell therapy on patients who progressed on two or more lines of systemic therapy, having tried at least one TKI combined with anti-programmed death-1 (PD-1)/ programmed death ligand 1 (PD-L1) immunotherapy or FOLFOX4 (5-fluorouracil, leucovorin, and oxaliplatin) chemotherapy.'

A similar strategy of focusing on subsequent lines of therapy was used by other companies studying adoptive cellular therapy for HCC in the early-stage development including Immunotech Biopharm, Immunicum AB, Eureka Therapeutics, Adaptimmune Therapeutics, Fate Therapeutics, and Origincell Therapeutics. Therefore, investigation of heavily pretreated advanced HCC patients seems to be a general trend with CAR-T cell developers in HCC.

Emamzadeh adds: 'The HCC clinical pipeline is crowded with me-too drugs targeting patients in the first-line setting. CARsgen's CAR-GPC3 T cell therapy is a first-in-class targeted drug addressing advanced HCC patients who have progressed on or developed resistance to previous therapy-a patient population with little to no treatment options. GlobalData expects that if successful in later stage trials, CARsgen's therapy will be beneficial to underserved patients in late-stage advanced HCC.'


GlobalData plc published this content on 18 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 June 2021 17:30:05 UTC.

© Publicnow 2021
All news about GLOBALDATA PLC
07/30GLOBALDATA : UK local authorities keen on gigabit broadband but not Internet of ..
07/30GLOBALDATA : Job postings in the UAE have increased by 148% since July 2020 larg..
07/30GLOBALDATA : ESG disruption will shake up oil and gas market and is an opportuni..
07/30GLOBALDATA : Upcoming LBPs could be the answer for GI patients with no approved ..
07/30GLOBALDATA : Early-stage funding rounds account for over 68% of Asia-Pacific VC ..
07/30GLOBALDATA : Lam Research ramps up hires in Malaysia, focuses on manufacturing, ..
07/29GLOBALDATA : US COVID-19 testing shouldn't overshadow testing for other diseases..
07/29GLOBALDATA : Hungary unlikely to meet its Zrínyi 2026 spending target due to eco..
07/29GLOBALDATA : Automakers collaborate to lead all-inclusive electrification in Jap..
07/29GLOBALDATA : Venture capital investors continue to bet big on low value deals in..
More news
Sales 2021 191 M 266 M 266 M
Net income 2021 28,6 M 39,8 M 39,8 M
Net Debt 2021 40,8 M 56,7 M 56,7 M
P/E ratio 2021 69,2x
Yield 2021 1,10%
Capitalization 1 953 M 2 715 M 2 715 M
EV / Sales 2021 10,4x
EV / Sales 2022 9,74x
Nbr of Employees 3 472
Free-Float 30,8%
Duration : Period :
GlobalData Plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLOBALDATA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 5
Last Close Price 1 655,00 GBX
Average target price 1 586,25 GBX
Spread / Average Target -4,15%
EPS Revisions
Managers and Directors
Michael Thomas Danson Chief Executive Officer & Director
Graham Charles Lilley Chief Financial Officer, Secretary & Director
Murray Legg Independent Non-Executive Chairman
Peter Martin Harkness Independent Non-Executive Director
Catherine Birkett Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
S&P GLOBAL INC.30.42%103 270
RELX PLC17.94%56 656
MSCI INC.33.46%49 132
EQUIFAX INC.35.14%31 751